| Literature DB >> 18510748 |
Anne Sales1, Christian Helfrich, P Michael Ho, Ashley Hedeen, Mary E Plomondon, Yu-Fang Li, Alison Connors, John S Rumsfeld.
Abstract
BACKGROUND: Ischemic heart disease (IHD) affects at least 150,000 veterans annually in the United States. Lowering serum cholesterol has been shown to reduce coronary events, cardiac death, and total mortality among high risk patients. Electronic clinical reminders available at the point of care delivery have been developed to improve lipid measurement and management in the Veterans Health Administration (VHA). Our objective was to report on a hospital-level intervention to implement and encourage use of the electronic clinical reminders.Entities:
Year: 2008 PMID: 18510748 PMCID: PMC2423370 DOI: 10.1186/1748-5908-3-28
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
The VA Quality Enhancement Research Initiative (QUERI)
| The U.S. Department of Veterans Affairs' (VA) Quality Enhancement Research Initiative (QUERI) was launched in 1998. QUERI was designed to harness VA's health services research expertise and resources in an ongoing system-wide effort to improve the performance of the VA healthcare system and, thus, quality of care for veterans. |
| QUERI researchers collaborate with VA policy and practice leaders, clinicians, and operations staff to implement appropriate evidence-based practices into routine clinical care. They work within distinct disease- or condition-specific QUERI Centers and utilize a standard six-step process: |
| 1) Identify high-risk/high-volume diseases or problems. |
| 2) Identify best practices. |
| 3) Define existing practice patterns and outcomes across the VA and current variation from best practices. |
| 4) Identify and implement interventions to promote best practices. |
| 5) Document that best practices improve outcomes. |
| 6) Document that outcomes are associated with improved health-related quality of life. |
| Within Step 4, QUERI implementation efforts generally follow a sequence of four phases to enable the refinement and spread of effective and sustainable implementation programs across multiple VA medical centers and clinics. The phases include: |
| 1) Single-site pilot, |
| 2) Small-scale, multi-site implementation trial, |
| 3) Large-scale, multi-region implementation trial, and |
| 4) System-wide rollout. |
| Researchers employ additional QUERI frameworks and tools, as highlighted in this |
Intervention and comparison facility descriptions
| Small non-tertiary facility in a relatively small city; frontier state | Large tertiary teaching center in a large metropolitan area with several smaller clinics in outlying areas | Very small non-tertiary facility in a small city in extremely remote area | Relatively large non-tertiary outpatient only facility with several smaller clinics in outlying areas | Small non-tertiary facility in a relatively small city; frontier area | Large tertiary teaching center in a large metropolitan area with several smaller clinics in outlying areas | |
| 1883 | 4440 | 1001 | 4021 | 1399 | 5763 | |
| 14 | 60 | 9 | 22 | 11 | 83 | |
| 80% | 78% | 96% | 80% | 70% | 57% | |
| 65% | 53% | 79% | 62% | 71% | 33% | |
| 60% | 58% | 50% | 46% | 43% | 36% | |
| 57% | 46% | 81% | 28% | 73% | 43% | |
| 45% | 49% | 50% | 71% | 64% | 39% | |
| 3 of 8 | 8 of 21 | 4 of 9 | NA | |||
| 1 MD, 2 RNs | 1 QM, 1 Admin, 6 NPs or PAs | 2 MDs, 2 RNs | ||||
PCP-Primary Care Provider
Figure 1Percentage of patients at each of the three intervention sites with diagnosed IHD who had LDL-c measurement reminders due from May to September 2003.
Figure 2Percentage of patients at each of the three intervention sites who had a diagnosis of IHD and an elevated LDL-c measurement for whom treatment reminders were due from May to September 2003.
Patient characteristics in both intervention and comparison VHA hospitals at baseline
| 69.0 (s.d. 10.3) | 70.7 (s.d. 9.6) | <0.001 | |
| 98.2 | 98.6 | 0.02 | |
| 66% | 68% | 0.02 | |
| 62% | 55% | <0.001 | |
| 0.99 (s.d. 1.01) | 0.98 (s.d.0.98) | 0.68 | |
| 91.2% | 94.0% | <0.001 | |
| 79.6% | 80.2% | 0.884 | |
Process outcomes: Reminder reports (Intervention hospitals only)
| 720 | 1404 | 475 | |
| 27% | 19% | 21% | |
| 20% | 15% | 23% | |
| 10% | 14% | 11% | |
| 11% | 8% | 13% |
Process outcomes: Provider survey responses
| Proportion of primary care clinicians who report using any electronic reminders whether the national IHD reminders or not *(from provider survey) | 88.4% | 98.2% | 0.04 | 64.3% | 94.9% | 93.7% | 0.01 | 100% | 100% | 96.4% | 0.59 |
| Proportion reporting frequent use of IHD electronic reminders | 38.4% | 20.3% | 0.01 | 30.0% | 36.4% | 50.0% | 0.38 | 45.8% | 21.4% | 2.8% | <0.001 |
| Proportion reporting that IHD electronic reminders are very useful | 32.3% | 16.2% | 0.02 | 35.0% | 29.1% | 37.5% | 0.77 | 37.5% | 14.3% | 2.8% | 0.001 |
| Proportion reporting that IHD electronic reminders increase awareness of lipid monitoring for IHD patients | 30.3% | 14.9% | 0.02 | 30.0% | 25.4% | 41.7% | 0.35 | 29.2% | 21.4% | 2.8% | 0.008 |
| Proportion reporting that electronic reminder screens provide appropriate treatment/action options | 27.3% | 14.9% | 0.06 | 25.0% | 23.6% | 37.5% | 0.48 | 37.5% | 7.1% | 2.8% | |
*Comparison sites had access to electronic IHD reminders, but were not encouraged to turn them on, nor was the implementation intervention deployed at these sites.
Summative outcomes: The proportion of patients with current LDL-c measurements and patients prescribed lipid lowering medications from baseline to the end of intervention period
| Odds ratio for change from baseline to end of intervention without adjusting for degree of implementation (95% confidence intervals)* | |||||||
| Effect on proportion of patients with current LDL-c from baseline to end of intervention period¶ | Reference | ||||||
| Effect on proportion of patients on lipid-lowering medications from baseline to intervention period¶ | 0.92 (0.72,1.19) | Reference | |||||
| Odds ratio for change from baseline to end of intervention adjusting for provider self-reported amount of use of IHD reminder (95% CI) | |||||||
| Effect on proportion of patients with current LDL-c from baseline to end of intervention period | 1.33 (0.93,1.89) | 1.46 (0.77,2.76) | Reference | ||||
| Effect on proportion of patients on lipid-lowering medications from baseline to intervention period | 0.87 (0.67,1.13) | 0.85 (0.71,1.03) | 1.05 (0.82,1.35) | 1.35 (0.97,1.90) | Reference | ||
*Adjusted for patient baseline and facility characteristics in Table 2; odds ratios significant at p < 0.05 bolded
§Intra-class correlation for measurement change was 0.08, 95% CI 0.00 – 0.18
¶Intra-class correlation for treatment change was 0.02, 95% CI 0.00 – 0.05